The DOI matches its Crossref record.
Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy [see comments]
Open accessAbstract
Myelodysplastic syndrome (MDS) is a complication of conventional antineoplastic therapy but has rarely been reported after autologous bone marrow transplantation (ABMT). We reviewed records of 206 patients who underwent ABMT for lymphoma at the University of Minnesota (Minneapolis, MN) between 1974 and 1993. Of 206 patients who underwent ABMT for non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD), 9 patients developed an MDS or secondary acute leukemia between 5 and 60 months (median 34 months) post-BMT. Two patients had relapsed after transplant and received additional therapy before the diagnosis of MDS. They were censored from the statistical analysis, resulting in a cumulative incidence of 14.5% +/- 11.6% (95% confidence interval) at 5 years. Three patients (15.2% +/- 18.0%) had HD, and four (14.0% +/- 14.7%) had NHL. In vitro BM purging had no affect on the incidence of MDS, although patients receiving peripheral blood stem cells had a projected MDS incidence of 31% +/- 33% versus 10.5% +/- 12% if BM cells were used (p = .0035). The patients had received a median of 14 cycles (range, 6 to 40) of chemotherapy before autologous transplantation; Five of nine patients received radiation therapy before BMT conditioning, and all patients received radiation before the diagnosis of MDS. No BM cytogenetic abnormalities were evident pretransplant in three of three patients studied, and all nine had normal pretransplant BM morphology. All patients had morphologic BM findings typical of MDS, and six of six studied had clonal cytogenetic abnormalities. At the diagnosis of MDS, all nine patients were without clinical, radiographic, or autopsy evidence of recurrent lymphoma; Three of the nine patients have died from complications of cytopenias at 23, 36, and 45 months after transplant (3 to 10 months after the diagnosis of MDS), whereas 6 survive 8 to 63 months after transplantation (1 to 34 months post-MDS). These data emphasize the cumulative leukemogenic potential of standard and salvage radiation and chemotherapy regimens and highlight treatment-induced MDS as an important and frequent late complication of potentially curative BM transplant therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,825
Malignant neoplasms following bone marrow transplantation
Bhatia, S., Ramsay, N., Steinbuch, M., Dusenbery, K., Shapiro, R., Weisdorf, D., Robison, L., Miller, J., & Neglia, J. (1996) · Blood · doi:10.1182/blood.v87.9.3633.bloodjournal8793633 · Cited by 410
Self-citationFreedman, A. S., Neuberg, D., Mauch, P., Soiffer, R. J., Anderson, K. C., Fisher, D. C., Schlossman, R., Alyea, E. P., Takvorian, T., Jallow, H., et al. (1999) · Blood · doi:10.1182/blood.v94.10.3325.422k13_3325_3333 · Cited by 349
Press, O. W., Eary, J. F., Gooley, T., Gopal, A. K., Liu, S., Rajendran, J. G., Maloney, D. G., Petersdorf, S., Bush, S. A., Durack, L. D., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2934 · Cited by 325
Baker, K. S., DeFor, T. E., Burns, L. J., Ramsay, N. K. C., Neglia, J. P., & Robison, L. L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.108 · Cited by 317
Self-citation
Metadata
- Authors
- Miller, J., Arthur, D., Litz, C., Neglia, J., Miller, W., & Weisdorf, D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1994-06-15
- Volume
- 83
- Issue
- 12
- Pages
- 3780-3786
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2395585278
- Cited by
- 234
- References
- 0
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy [see comments]. https://app.cochat.ai/papers/10.1182/blood.v83.12.3780.3780
- The paper
- Miller, J., Arthur, D., Litz, C., Neglia, J., Miller, W., & Weisdorf, D. (1994). Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy [see comments]. Blood. https://doi.org/10.1182/blood.v83.12.3780.3780
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.